Sevin Rosen Re-Ups Investment In Antibody Developer

Dallas-based venture investor Sevin Rosen Funds has re-upped its backing of antibody developer Alder BioPharmaceuticals, participating as part of a $38M Series D funding for that company. Alder said that its new round was led by Novo Ventures, but also included Sevin Rosen and Ventures West, WRF Capital, H.I.G. Ventures, Delphi Ventures and TPG Biotech. Steve Dow of Sevin Rosen Funds is Chairman of Alder BioPharmaceuticals. Alder's antibody technology is being used to treat cancer, autoimmune diseases, and is also applicable to other conditions. The company is based in Bothell, Washington. More information »